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However, in vivo analysis has not been carried out to date to assess the physiological relevance of these findings in the B cell compartment. Moreover, the function of Daxx in the modulation of the apoptotic response is also extremely controversial, probably because of lack of in vivo genetic analysis. In this study, we show in lymphoid-restricted transgenic mice that Daxx is indeed involved in the regulation of B cell function in vivo, albeit in an unanticipated manner.
We previously demonstrated that Concavalin A (Con A), which is mainly a T-specific activation agent, causes Daxx induction in B cells. 1 As this effect could be due to a cross talk between T and B cells, we investigated what mechanism could be involved. T helper cells (Th) can activate B cells through the interaction between CD40 Ligand (CD40L) and CD40. 15 We therefore tested whether Daxx induction in B cells was due to this interaction by using an antagonist anti-CD40L antibody. While Daxx was clearly induced upon ConA stimulation in B cells, its induction was substantially reduced in cells treated with blocking antibodies (Figure 1a ). The expression of the CD40L-induced molecule [16] [17] [18] [19] FAS was blocked by the ConA/anti-CD40L antibody combined treatment ( Figure 1a) . Moreover, stimulation of purified B220-positive B cells triggered a clear induction of Daxx at the protein level (Figure 1b) . Treatment with another B cellactivating stimulus, lipopolysaccaride (LPS), had comparable effects ( Figure 1b) . The induction of Daxx was concomitant with the one of FAS and BCL-X L , two transcriptional targets of CD40 stimulation (Figure 1b) . [16] [17] [18] [19] [20] [21] Daxx was induced at the transcriptional level, and its induction was concomitant with the one of FAS (Figure 1c) .
We determined the role of Daxx in B-cell activation in vivo by generating Daxx transgenic animals. A Daxx cDNA was cloned under the control of a promoter composed by the proximal lck promoter and the em enhancer, which is known to drive expression of the transgene in both thymocytes and B cells (Supplementary Figure 1A) . 22 Two transgenic lines were generated and Daxx expression was analyzed. Daxx transgenic animals were fertile and viable. Daxx mRNA was overexpressed at high levels in spleen, bone marrow (BM) and thymus (Supplementary Figure 1B) . By contrast, the transgene was not expressed in other organs such as lung, liver and heart (Supplementary Figure 1B) . Overexpressed Daxx was predominantly nuclear and accumulates in PML nuclear bodies (PML-NB) (Supplementary Figure 1C) . Daxx was clearly overexpressed at the protein level in spleen and thymus (Supplementary Figure 1D) . While we found that Daxx was induced upon CD40 stimulation in control cells, constitutively high Daxx levels were observed in both untreated and CD40-treated transgenic cells (Supplementary Figure 1E) . We investigated if Daxx overexpression would alter B and/or T-cell differentiation. To this end, cells from bone marrow, spleen and thymus were isolated and analyzed for surface markers to identify various subpopulations. pro-B (B220 þ / CD43 þ ), pre-B (B220 þ /CD43À) and mature B (B220 þ / IgM þ ) cells were equally represented in control and transgenic bone marrows (Supplementary Table S2) . Moreover, transgenic spleens contained equal numbers of plasma cells (B220 þ /CD138 þ ) and surface immunoglobulin-expressing B cells (IgD and IgM, Supplementary Table S2) . Although the Daxx transgene was highly expressed in thymocytes, thymic development was not affected either (not shown).
Daxx is expressed at very low levels in bone marrow and spleen (Supplementary Figure 1B) , but is markedly induced upon CD40 engagement (Figure 1a Daxx has been proposed to bind the FAS receptor and to positively mediate FAS-induced apoptosis. 2, 4, 8 Resting mature B cells are resistant to FAS-induced cell death. 21 By contrast, upon CD40 stimulation, B cells become sensitive to FAS-L-induced apoptosis through the upregulation of FAS. [17] [18] [19] CD40-stimulated cells were incubated with different concentrations of anti-FAS antibodies for 12 h. While apoptosis was rapidly induced in control cells (over three-fold induction of apoptosis at all concentrations tested: Figure 2d ), transgenic cells were not more sensitive to FAS-induced apoptosis (Figure 2d ). By contrast, we could observe a moderate, but consistent reduction in cell death. Interestingly, FAS-induced apoptosis was unaffected in Daxx-transduced MEFs (not shown). Thus, Daxx does not enhance, but rather suppresses FAS-induced apoptosis in primary B cells.
CD40 signalling results in the concomitant induction of both FAS and the anti-apoptotic molecule BCL-X L .
16-19,21 FAS induction was comparable in both control and transgenic cells (Supplementary Figure S3) . Conversely, BCL-X L was induced at a higher extent in transgenic cells (Figure 2e ), thus suggesting that higher levels of BCL-X L could counteract FAS-induced apoptosis.
In both B-cell malignancies and autoimmune disorders, B cells are resistant to apoptosis and express high levels of CD40-L, thus indicating the existence of either autocrine or paracrine homotypic B cell interactions to promote survival and proliferation. 15 At the same time, CD40 stimulation of B cells by T helper cells results in FAS upregulation and sensitization to FAS-induced apoptosis.
16-18 Thus, CD40 stimulation can lead either to protection from apoptosis or sensitization to apoptosis depending on the stage of differentiation and microenvironmental conditions. In this study, we demonstrate in vivo, in transgenic mice, that Daxx operates downstream CD40 in an unforeseen manner: 
